{"id":"NCT00302081","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)","officialTitle":"Comparison of Three Regimens of PEG-Intron and Ribavirin in the Treatment of Chronic Hepatitis C, Genotype 2 or 3, in Previously Untreated Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-08","primaryCompletion":"2008-04","completion":"2008-04","firstPosted":"2006-03-13","resultsPosted":"2009-08-11","lastUpdate":"2017-04-05"},"enrollment":696,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"BIOLOGICAL","name":"peginterferon alfa-2b (SCH 54031)","otherNames":["PegIntron (SCH 54031)"]},{"type":"BIOLOGICAL","name":"peginterferon alfa-2b (SCH 54031)","otherNames":["PegIntron (SCH 54031)"]},{"type":"BIOLOGICAL","name":"peginterferon alfa-2b (SCH 54031)","otherNames":["PegIntron (SCH 54031)"]},{"type":"DRUG","name":"ribavirin (SCH 18908)","otherNames":["REBETOL (SCH 18908)"]},{"type":"DRUG","name":"ribavirin (SCH 18908)","otherNames":["REBETOL (SCH 18908)"]}],"arms":[{"label":"PEG2b 1.5/R (24 weeks)","type":"ACTIVE_COMPARATOR"},{"label":"PEG 2b 1.0/R (24 weeks)","type":"EXPERIMENTAL"},{"label":"PEG2b 1.5/R (16 weeks)","type":"EXPERIMENTAL"}],"summary":"This is a randomized, open-label, multinational study designed to evaluate the \"standard\" regimen, PegIntron 1.5 µg/kg subcutaneously once weekly plus ribavirin 800-1200 mg daily \\[Arm PEG2b 1.5/R (24 weeks)\\], compared to a lower dose regimen, PegIntron 1.0 µg/kg subcutaneously once weekly plus ribavirin 800-1200 mg daily \\[Arm PEG2b 1.0/R (24 weeks)\\], using a 24 week treatment duration for both arms. Additionally, the study examined the efficacy of reduced treatment duration: PegIntron 1.5 µg/kg subcutaneously once weekly plus ribavirin 800-1200 mg for 16 weeks \\[Arm PEG2b 1.5/R (16 weeks)\\] .","primaryOutcome":{"measure":"The Number of Participants Who Achieve a Sustained Virologic Response (SVR)","timeFrame":"24-week treatment duration for Arms [Peg2b 1.5/R(24 weeks)] and [PEG2b 1.0/R(24 weeks]); 16-week treatment duration for Arm [PEG2b 1.5/R(16 weeks]. Follow-up of 24 weeks for each arm.","effectByArm":[{"arm":"PEG2b 1.5/R (24 Weeks)","deltaMin":153,"sd":null},{"arm":"PEG2b 1.0/R (24 Weeks)","deltaMin":144,"sd":null},{"arm":"PEG2b 1.5/R (16 Weeks)","deltaMin":129,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.041"},{"comp":"OG000 vs OG002","p":"0.495"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":17,"exclusionCount":18},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21237227"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":230},"commonTop":["PYREXIA","HEADACHE","ASTHENIA","FATIGUE","ALOPECIA"]}}